Details of the Drug

General Information of Drug (ID: DMIAZFP)

Drug Name

BBP-631

Indication

Disease Entry	ICD 11	Status	REF
Congenital adrenal hyperplasia	5A71.01	Phase 1/2	[1]
------------------------------------------------------------------------------------

Drug Type

Gene therapy

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04783181) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of the Safety and Efficacy of Gene Therapy for Congenital Adrenal Hyperplasia Through Administration of an Adeno-Associated Virus (AAV) Serotype 5-Based Recombinant Vector Encoding the Human CYP21A2 Gene. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Adrenas Therapeutics